Why Can't I Get Mounjaro? What's Actually Standing in the Way

You may not meet the licensed eligibility criteria

The most common reason a prescriber declines Mounjaro is straightforward: the person asking doesn't fall within the licensed indication. In the UK, tirzepatide is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition. That condition list includes type 2 diabetes, prediabetes, hypertension, dyslipidaemia and obstructive sleep apnoea, among others. A BMI of 29.5 with no qualifying comorbidities, for example, sits outside the licence, and a responsible prescriber won't work around that.

BMI thresholds are adjusted downward by 2.5 kg/m² for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance, so if you're close to a threshold it's worth knowing that. You can check your BMI using the NHS BMI calculator before you enquire anywhere. If you want to read more about the full picture of who tirzepatide is approved for, the Mounjaro overview page sets that out in detail.

It's also worth remembering that the licence is a floor, not a ceiling. Even when the numbers fit, a prescriber looks at your full health picture: current medications, any history of pancreatitis, thyroid conditions, kidney function and so on. A refusal after clinical review isn't a door slammed permanently, it may simply mean that right now, on that assessment, the risk-benefit balance didn't stack up in your favour. If side effects such as disrupted sleep while taking Mounjaro have come up during your clinical review, those too can factor into how a prescriber weighs things up.

NHS access is much narrower than most people realise

If you've been trying to get Mounjaro through your GP and been turned away, that's almost certainly an NHS eligibility issue, not a safety one. NICE recommended tirzepatide for NHS use in England in December 2024, but the rollout is deliberately phased. The current cohort (active since June 2025) is limited to people with a BMI of 40 or above and four or more of a specific list of qualifying conditions. A second cohort (BMI 35–39.9 with four or more conditions) opened in June 2026, but the criteria remain tight. You can read the full NICE recommendations in Technology Appraisal TA1026.

Even within those thresholds, your GP practice has to have opted into the new prescribing arrangement, and you'd need to be enrolled in a wrap-around diet and activity support programme. Meeting the criteria on paper doesn't automatically mean your practice is ready to prescribe. Criteria differ in Scotland, Wales and Northern Ireland, so if you're outside England the position may vary further.

For a lot of people reading this, the NHS route is simply not open yet. That's not a reflection of need, it's the pace of a phased public rollout. The private route through a regulated pharmacy exists precisely for this gap. If you're weighing up the cost side of that, our page on Mounjaro affordability is worth reading alongside this one.

A private pharmacy has declined after reviewing your consultation

A private prescription refusal can sting, especially when you've paid for a consultation. But it's the system working as intended. GPhC-registered online pharmacies are required to have a qualified Independent Prescriber personally assess every request, not an algorithm, not an automated score, a named clinician. At nume, that review happens the same day, seven days a week, and the prescriber considers the whole clinical picture, not just the headline BMI figure.

Common clinical reasons for a private refusal include: current use of a medicine that interacts with tirzepatide, a history of a condition that sits in the contraindication list, or a dose-increase request without sufficient documented evidence of treatment progress. If you've been refused elsewhere and want to understand why, the most useful step is to ask the prescribing service for the clinical reason in writing, you're entitled to that.

Equally, if you're moving from another provider and want a clinical second opinion, our prescribers at nume review transfer patients with the same care as new ones, evidence of your current treatment is part of that process. A question our prescribers hear regularly is whether a refusal from one service means a permanent no everywhere; usually it doesn't, but the underlying clinical concern needs to be addressed rather than bypassed.

Stock and availability, a real but temporary barrier

Mounjaro availability has been uneven at certain strengths since demand grew sharply after 2023. This isn't unique to any one pharmacy; it reflects pressures across the licensed UK supply chain. The important point is that a legitimate pharmacy will tell you clearly when a strength is out of stock rather than substitute something unverified. The MHRA has warned publicly about fake tirzepatide pens being sold online, including a November 2025 raid on an illicit UK manufacturing operation, the MHRA Yellow Card scheme is the right place to report any suspect seller or product.

If you're mid-treatment and a specific pen strength is unavailable, that's a conversation for your prescriber, not something to solve by sourcing elsewhere. Holding at your current dose while a strength is temporarily unavailable is a clinical decision, not a commercial one. You can also read about what to look for when choosing where to get Mounjaro on our guide to sourcing it safely in the UK.

Timing can play into this too, orders placed around bank holidays, or the Monday rush after a long weekend, can affect dispatch windows. If you're planning ahead, knowing that orders placed by 12pm on a working day are dispatched the same day once approved helps you build in a buffer. That practical detail matters more than people expect when you're trying to stay on schedule. If you're not yet on treatment and want to understand how the process works end to end, how to get Mounjaro through a private pharmacy walks through every step.